Summary of deaths in patients who died within 6 months of randomization, in the ITT population
| Parameter, n (%) . | Ide-cel (n = 254) . | SRs (n = 132) . |
|---|---|---|
| Patients who died within 6 mo of randomization | 30 (12) | 9 (7) |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 8 (3) | 3 (2) |
| Death from malignant disease or its complication | 18 (7) | 6 (5) |
| Death from other cause∗ | 4 (2) | 0 |
| Patients who did not receive study treatment and died | 17 (7) | 0 |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 3 (1) | 0 |
| Death from malignant disease or its complication | 13 (5) | 0 |
| Death from other cause | 1 (<1) | 0 |
| Patients who received study treatment and died | 13 (5) | 9 (7) |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 5 (2) | 3 (2) |
| Death from malignant disease or its complication | 5 (2) | 6 (5) |
| Death from other cause | 3 (1) | 0 |
| Parameter, n (%) . | Ide-cel (n = 254) . | SRs (n = 132) . |
|---|---|---|
| Patients who died within 6 mo of randomization | 30 (12) | 9 (7) |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 8 (3) | 3 (2) |
| Death from malignant disease or its complication | 18 (7) | 6 (5) |
| Death from other cause∗ | 4 (2) | 0 |
| Patients who did not receive study treatment and died | 17 (7) | 0 |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 3 (1) | 0 |
| Death from malignant disease or its complication | 13 (5) | 0 |
| Death from other cause | 1 (<1) | 0 |
| Patients who received study treatment and died | 13 (5) | 9 (7) |
| Primary cause of death | ||
| Death from AE (not otherwise specified) | 5 (2) | 3 (2) |
| Death from malignant disease or its complication | 5 (2) | 6 (5) |
| Death from other cause | 3 (1) | 0 |
All 4 cases of “death from other cause” in the ide-cel arm were reported verbatim as “unknown,” which was coded under the system organ class of “general disorder and administration site condition.”